Answers are grounded in this paper and cite their sources.
Proposal demonstrates a multi-phase strategy to reactivate and neutralize latent viruses, suggesting improved antiviral treatments.
Latent viral infections, such as those caused by Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), and Epstein-Barr Virus (EBV), remain a major obstacle to achieving complete viral eradication. These pathogens establish dormancy within host cells, effectively evading immune detection and undermining standard antiviral therapies. This research proposal outlines a three-phase strategy that integrates nanotechnology and molecular biology to selectively reactivate latent viruses and eliminate them through targeted capture and neutralization mechanisms. By employing biomimetic nanostructures and phase-specific activation triggers, this approach seeks to minimize off-target effects and collateral damage, offering a controlled and replicable platform for treating chronic viral infections.
No takes yet. Share an insight, caveat, or question.
Pedro José García Gil (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: